|
|
Article: Pluristem Certified as a Good Manufacturing Practices (GMP) Site for the Manufacture of PLX cells for its Clinical Trials.
- Article from:
- Business Wire
- Article date:
- June 25, 2008
CopyrightCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NEW YORK -- Pluristem Therapeutics Inc. (NASDAQ:PSTI); (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of degenerative, ischemic and autoimmune indications, today announced that the Company has received certification that its manufacturing facility in Haifa, Israel has been approved as a Good Manufacturing Practices (GMP) standard site for the purpose of manufacturing PLX cells which will be shipped to the EU for use in the Company's upcoming clinical trials. Pluristem was awarded this certification by Biotec Distribution Wales, Ltd., the designee of the Paul Ehrlich Institute, ...